New lung cancer cocktail aims to outperform current standard
NCT ID NCT07170995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding a new drug (SHR-8068) to a standard immunotherapy (adebrelimab) and chemotherapy works better than the current standard (tislelizumab plus chemo) for people with advanced non-small cell lung cancer. About 460 participants will be randomly assigned to one of the two treatments. The study measures how long people live without their cancer getting worse and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-8068, adebrelimab, and platinum-based chemotherapy
- What this could lead to
- If this works, it could offer a new first-line treatment option for advanced lung cancer that may be more effective than current standard therapy.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not guaranteed. The new combination may not improve survival or could cause more side effects than the standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, 250117, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
- New pfizer drug shows promise against tough cancers
- New drug cocktail aims to shrink Hard-to-Treat lung tumors
- New hope for advanced lung cancer: drug cocktails under trial
- New shot may simplify lung cancer treatment, phase 3 trial underway
- New combo aims to outperform chemo in tough lung cancers